Klebsiella Pneumoniae Infections - Pipeline Insight, 2024

This Klebsiella Pneumoniae Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Klebsiella Pneumoniae Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Klebsiella Pneumoniae Infections Understanding

Klebsiella Pneumoniae Infections: Overview

Klebsiella pneumoniae is one of a handful of bacteria that are now experiencing a high rate of antibiotic resistance secondary to alterations in the core genome of the organism. Alexander Fleming first discovered resistance to beta-lactam antibiotics in 1929 in gram-negative organisms. Since that time, K. pneumoniae has been well studied and has been shown to produce a beta-lactamase that causes hydrolysis of the beta-lactam ring in antibiotics. Host protection from bacterial invasion mainly depends on two things: polymorphonuclear granulocytes, which phagocytose the bacteria, and serum complement proteins, which are bactericidal. The alternate pathway of complement activation is more active in Klebsiella pneumoniae infection. Neutrophil myeloperoxidase and lipopolysaccharide-binding protein facilitate in defense against Klebsiella pneumoniae infection. To get a Klebsiella infection, a person must be exposed to the bacteria. For example, Klebsiella must enter the respiratory (breathing) tract to cause pneumoniae, or the blood to cause a bloodstream infection.In healthcare settings, Klebsiella bacteria can be spread through person-to-person contact (for example, from patient to patient via the contaminated hands of healthcare personnel, or other persons) or, less commonly, by contamination of the environment. The bacteria are not spread through the air.Patients in healthcare settings also may be exposed to Klebsiella when they are on ventilators (breathing machines), or have intravenous (vein) catheters or wounds (caused by injury or surgery). Unfortunately, these medical tools and conditions may allow Klebsiella to enter the body and cause infection. Klebsiella infections that are not drug-resistant can be treated with antibiotics. Infections caused by KPC-producing bacteria can be difficult to treat because fewer antibiotics are effective against them. In such cases, a microbiology laboratory must run tests to determine which antibiotics will treat the infection. If the healthcare provider prescribes an antibiotic, patients must take it exactly as the healthcare provider instructs. Patients must complete the prescribed course of medication, even if symptoms are gone. If treatment stops too soon, some bacteria may survive and the patient may become re-infected. Patients must wash their hands as often as possible and follow all other hygiene recommendations.

Klebsiella Pneumoniae Infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella Pneumoniae Infections pipeline landscape is provided which includes the disease overview and Klebsiella Pneumoniae Infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella Pneumoniae Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella Pneumoniae Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Klebsiella Pneumoniae Infections. The therapies under development are focused on novel approaches to treat/improve Klebsiella Pneumoniae Infections.

Klebsiella Pneumoniae Infections Emerging Drugs

VXN-319: Vaxxilon
VXN-319 is a semi-synthetic multivalent vaccine candidate targeting Klebsiella pneumoniae strains. VXN-319 is a carbohydrate based vaccine currently at the lead optimization stage. Vaxxilon estimates it would provide protection against more than 80% of carbapenem resistant strains. Vaxxilon synthesizes the carbohydrates that resemble the sugar coating which surrounds each bacterial cell. The synthetic carbohydrates are then combined with other components to create conjugate vaccines similar to those that have been approved to prevent infections from bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type B.

Klebsiella Pneumoniae Infections: Therapeutic Assessment

This segment of the report provides insights about the Klebsiella Pneumoniae Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Klebsiella Pneumoniae Infections

There are approx. 5+ key companies which are developing the therapies Klebsiella Pneumoniae Infections. The companies which have their Klebsiella Pneumoniae Infections drug candidates in the most advanced stage, i.e phase I/II include Limma TechBiologics

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Klebsiella Pneumoniae Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Klebsiella Pneumoniae Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella Pneumoniae Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella Pneumoniae Infections drugs.

Klebsiella Pneumoniae Infections Report Insights

• Klebsiella Pneumoniae Infections Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Klebsiella Pneumoniae Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Klebsiella Pneumoniae Infections drugs?
• How many Klebsiella Pneumoniae Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Klebsiella Pneumoniae Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Klebsiella Pneumoniae Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Klebsiella Pneumoniae Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nomad Bioscience
• Centivax
• Limma TechBiologics
• Vaxxilon

Key Products

• Klebsiella pneumoniae Research Project
• Klebsiella infections research project
• Klebsiella pneumoniae tetravalent bioconjugate vaccine
• VXN 319